Showing results (31-40 of 226) with videos related to
Sort By:
Pageof 23
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 10, 2014
In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitorsAnne M Filppula, Pertti J Neuvonen, Janne T BackmanClinical Pharmacology and Therapeutics|June 18, 2003
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearanceCarl Kyrklund, Janne T Backman, Mikko Neuvonen, et al.Pharmacology Research & Perspectives|June 4, 2021
Health service use and costs associated with fluoroquinolone-related tendon injuriesLaura S M Kuula, Janne T Backman, Marja L BlomBritish Journal of Clinical Pharmacology|January 30, 2004
Effect of rifampicin on pravastatin pharmacokinetics in healthy subjectsCarl Kyrklund, Janne T Backman, Mikko Neuvonen, et al.Clinical Pharmacology and Therapeutics|April 5, 2012
Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple dosesJ Honkalammi, M Niemi, P J Neuvonen, et al.Clinical Pharmacology and Therapeutics|March 28, 2019
Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and InterpretationAleksi Tornio, Anne M Filppula, Mikko Niemi, et al.The Journal of Antimicrobial Chemotherapy|May 8, 2000
Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failureM Valtonen, E Tiula, J T Backman, et al.Clinical Pharmacology and Therapeutics|March 4, 2011
Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humansJ Honkalammi, M Niemi, P J Neuvonen, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 23, 2011
Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil dosesJohanna Honkalammi, Mikko Niemi, Pertti J Neuvonen, et al.Pharmacology Research & Perspectives|February 16, 2022
Healthcare costs and mortality associated with serious fluoroquinolone-related adverse reactionsLaura S M Kuula, Janne T Backman, Marja L BlomPageof 23